Clinical trials in Porto – page 17

498 clinical trials in Porto, Portugal across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Porto at a glance

498

clinical trials

Research sites5

Quick filters

498 trials in Porto

Open in trial search

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Cenegermin
Sponsor:Dompe' Farmaceutici S.p.A.

Contact Research Centre

Adrenogenital syndrome

Not yet recruiting

Study of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Androgen Levels

InvestigationalNo placebo

Study of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Androgen Levels

InvestigationalNo placebo

Portugal

Participants:18–64 years
Substances:Crinecerfont
Sponsor:Neurocrine Biosciences Inc.

Contact Research Centre

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Dry age-related macular degeneration

Not yet recruiting

A study to evaluate the safety and effectiveness of ADX-038 in adults with geographic atrophy caused by age-related macular degeneration.

Registered drug

A study to evaluate the safety and effectiveness of ADX-038 in adults with geographic atrophy caused by age-related macular degeneration.

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:ADX-038
Sponsor:Adarx Pharmaceuticals Inc.

Contact Research Centre

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Admilparant
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Acquired ATTR amyloidosis

Not yet recruiting

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Acoramidis Hydrochloride
Sponsor:Eidos Therapeutics Inc.

Contact Research Centre

K-ras gene mutation+2

Not yet recruiting

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Gastrointestinal stromal tumour

Not yet recruiting

Study of DCC-3116 and ripretinib combination therapy in patients with advanced gastrointestinal stromal tumor (GIST)

Registered drugNo placebo

Study of DCC-3116 and ripretinib combination therapy in patients with advanced gastrointestinal stromal tumor (GIST)

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:DCC-3116
Sponsor:Deciphera Pharmaceuticals Inc.

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Hepatitis alcoholic+1

Not yet recruiting

Study on the Safety and Effects of Resatorvid and Filgrastim for Patients with Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure

Registered drug

Study on the Safety and Effects of Resatorvid and Filgrastim for Patients with Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Filgrastim
Sponsor:Alpha Bioresearch S.L.

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Porto

What the registry says about research in the country

01 Ophthalmology & Rare Diseases

Innovative research focusing on polypoidal choroidal vasculopathy and rare genetic conditions like PMM2-CDG, exploring new treatment approaches to improve patient outcomes.

Vision disorders
Genetic disorders
Treatment efficacy studies

02 Oncology & Hematology

Groundbreaking studies in chronic myelogenous leukemia, multiple myeloma, and advanced malignancies, including research on novel therapies for non-small cell lung cancer.

Blood cancers
Solid tumors
Immunotherapy

03 Dermatology & Immunology

Comprehensive research into conditions like hidradenitis suppurativa, plaque psoriasis, and pyoderma gangrenosum, evaluating new therapeutic approaches.

Inflammatory skin conditions
Autoimmune disorders
Novel biologics

04 Cardiology & Metabolic Disorders

Studies examining hypertrophic cardiomyopathy, familial hypercholesterolemia, and innovative treatments for obesity.

Heart conditions
Metabolic diseases
Weight management

05 Neurology & Genetic Disorders

Investigating treatments for Dravet Syndrome, menstrual migraine, and rare conditions like Niemann-Pick disease.

Neurological disorders
Rare diseases
Pain management

Back to Portugal All countries